Eli Lilly reported what it framed as top-tier weight-loss results for retatrutide in people with obesity and type 2 diabetes, highlighting outcomes from its Phase 3 program TRIUMPH-2. In the 12 mg arm, participants lost an average of 49.6 pounds (about 20%+ of body weight), with a large share also reaching obesity normalization by study end. Separately, Lilly also detailed combination results for its amylin-incretin approach eloraTZP at EASD26, where it said weight loss reached up to 23.3% in adults with obesity and diabetes. Together, the updates reinforce Lilly’s push into next-generation incretin-based regimens beyond first-wave GLP-1 agents. For the sector, the efficacy benchmarks intensify competition across obesity, while increasing pressure on dosing convenience, long-term durability, and cardiovascular risk management data before regulators and payers broaden coverage decisions.